by this decision-analysis process , the p & t committee recommended that all current third-generation cephalosporins ( cefotaxime , cefoperazone , and moxalactam ) be removed from the institutions 's formulary and be replaced with ceftazidime and ceftriaxone .
C0007554
cefotaxime
C0007561
ceftriaxone